What this study is
The purpose of this study is to measure the amount of a protein in the brain known as tau using an imaging procedure called Positron Emission Tomography (PET/CT). Tau has been shown to build up in the brains of patients with injury to brain cells. This study looks at neurodegenerative diseases such as frontotemporal degeneration (FTD).
What's being tested
- 18F-AV-1451
Intervention · DRUG
The experimental tracer used for this study is called 18F-AV-1451 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. Participants will undergo a baseline 18F-AV-1451 brain scan. If funding is available, participants will be asked to return for one or more longitudinal visits, including a 18F-AV-1451 brain scan, every 9 to 18 months after the prior visit. The 18F-AV-1451 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania.
Study details
- Official title
- Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease
- Sponsor
- University of Pennsylvania
- Conditions
- Neurodegenerative Disease
- Enrolling
- 300 people
- Starts
- 2016-08-23
- Est. completion
- 2030-09
- Design
- Open-label, single group, Phase 2, Phase 3
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years – 100 YearsSex ALLHealthy volunteers AcceptedNEURODEGENERATIVE SUBJECTS
You may qualify if
- Participants has been diagnosed with one of the following neurodegenerative diseases: FTD, PPA, CBD, PSP, MCI, AD, PCA, PD, PDD, DLB, MSA, ALS or FTD- ALS
- Participants will be 18 years of age or older
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures. If the subject is unable to provide informed consent, the subject's legal representative may consent on behalf of the patient, but the patient will be asked to confirm assent.
- Participants must be willing and able to comply with scheduled visits and imaging procedures.
- Subject is concurrently enrolled in centers UNICORN(842873) protocol.
You can't join if
- Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT.
- Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician
- Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
- The investigators may choose to exclude participants with clinically significant cardiovascular disease and/or documented abnormalities on ECG out of an abundance of caution.
- The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
HEALTHY CONTROL SUBJECTS
You may qualify if
- Participants will be 18 years of age or older.
- Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
- Participants must be willing and able to comply with scheduled visits and imaging procedures.
- Subject is concurrently enrolled in centers UNICORN(842873) protocol
You can't join if
- Pre-existing psychiatric conditions (e.g., active depression, schizophrenia, or active anxiety) or neurological conditions (e.g., stroke, epilepsy, head trauma) per medical record review or self-report.
- Current use of psychoactive medications or substances per medical record review or self-report.
- Females who are pregnant or breast feeding at the time of the baseline PET/CT scan will not be eligible for this study. A urine pregnancy test will be performed in women of child-bearing potential at screening and within 24 hours of any scheduled PET/CT.
- Inability to tolerate or contraindication to imaging procedures in the opinion of an investigator or treating physician
- Any medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
- The investigators may choose to exclude participants with clinically significant cardiovascular disease and/or documented abnormalities on ECG out of an abundance of caution.
- The investigators of UNICORN (IRB #842873) have determined the participant has evidence of structural abnormalities such as major stroke or mass on MRI that is likely to interfere with analysis of the PET scan.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of Pennsylvania
Philadelphia, Pennsylvania, United States
- Dahlia Kamel · Contact215-662-6134kamel.dahlia@pennmedicine.upenn.edu
- David Irwin, MD · Principal investigator
Recruiting
Study team
Sponsor
University of Pennsylvania
Study ID 824867
Principal investigator
David Irwin, MD
University of Pennsylvania
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.